Alyssa Y. Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alyssa Y. Chen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Ajit Moghekar
Department of Critical Care Medicine, Cleveland Clinic, Cleveland, OH
2 shared publicationsAnita J. Reddy
Department of Critical Care Medicine, Cleveland Clinic, Cleveland, OH
2 shared publicationsEduardo Mireles-Cabodevila
Department of Critical Care Medicine, Cleveland Clinic, Cleveland, OH
2 shared publications- Jason R. Yerke
Cleveland Clinic
2 shared publications - Nicole Palm
Department of Pharmacy Cleveland Clinic Cleveland Ohio USA
2 shared publications Abhijit Duggal
Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA
1 shared publication
Latest Publications
- 20 February 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (5) , 331-339
Implementation of a novel insulin infusion calculator in the electronic health record medication administration record: Assessing efficacy and safety in intensive care unit patients
Introduction: Intravenous insulin infusions are recommended for control of hyperglycemia in critically ill patients. Institutions have adopted nurse‐driven titration protocols for management of infusions; however, optimal integration within electronic health records (EHRs) has lagged. Data is lacking regarding clinical pharmacist interventions in standardizing and implementing decision support with electronic nomograms.Methods: This multicenter cohort study aimed to evaluate the efficacy and safety of implementing an EHR medication administration record (MAR) calculator for insulin infusion in 29 hospital intensive care units (ICUs). Outcomes were evaluated before and after implementation of the EHR MAR calculator (April 12–June 5, 2023; implementation on May 9, 2023). The primary efficacy outcome was the proportion of blood glucose values within a target range of 140–179 mg/dL. Secondary outcomes included the proportions of hypoglycemic and hyperglycemic glucose values.Results: A total of 206 patients were included: 109 in the pre‐group and 97 in the post‐group. More patients in the pre‐group received corticosteroids (40.4% vs. 22.7%). The EHR MAR calculator implementation showed a significant increase in glucose values within the target range (35.5% post‐implementation vs. 31.0% pre‐implementation, p = 0.02). There were no significant differences in the occurrence of hypoglycemic events, but the rate of hyperglycemia decreased (549 [43.7%] post‐implementation, 601 [48.6%] pre‐implementation, p = 0.02).Discussion: This is the first study describing implementation of an integrated MAR calculator that automatically imports blood glucose results used for calculations in the MAR and does not rely on manual input by the nurse. The study demonstrated the benefits of transitioning from a paper‐based nomogram to an EHR MAR calculator for insulin infusion management in critically ill patients in improving time in target range and reducing the proportion of hyperglycemic values. Pharmacists provided standardization, validation, education, and assisted with implementation to streamline transitions of care, monitoring methods, and drug‐laboratory interaction concerns.
- 20 February 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (5) , 331-339
Implementation of a novel insulin infusion calculator in the electronic health record medication administration record: Assessing efficacy and safety in intensive care unit patients
Introduction: Intravenous insulin infusions are recommended for control of hyperglycemia in critically ill patients. Institutions have adopted nurse‐driven titration protocols for management of infusions; however, optimal integration within electronic health records (EHRs) has lagged. Data is lacking regarding clinical pharmacist interventions in standardizing and implementing decision support with electronic nomograms.Methods: This multicenter cohort study aimed to evaluate the efficacy and safety of implementing an EHR medication administration record (MAR) calculator for insulin infusion in 29 hospital intensive care units (ICUs). Outcomes were evaluated before and after implementation of the EHR MAR calculator (April 12–June 5, 2023; implementation on May 9, 2023). The primary efficacy outcome was the proportion of blood glucose values within a target range of 140–179 mg/dL. Secondary outcomes included the proportions of hypoglycemic and hyperglycemic glucose values.Results: A total of 206 patients were included: 109 in the pre‐group and 97 in the post‐group. More patients in the pre‐group received corticosteroids (40.4% vs. 22.7%). The EHR MAR calculator implementation showed a significant increase in glucose values within the target range (35.5% post‐implementation vs. 31.0% pre‐implementation, p = 0.02). There were no significant differences in the occurrence of hypoglycemic events, but the rate of hyperglycemia decreased (549 [43.7%] post‐implementation, 601 [48.6%] pre‐implementation, p = 0.02).Discussion: This is the first study describing implementation of an integrated MAR calculator that automatically imports blood glucose results used for calculations in the MAR and does not rely on manual input by the nurse. The study demonstrated the benefits of transitioning from a paper‐based nomogram to an EHR MAR calculator for insulin infusion management in critically ill patients in improving time in target range and reducing the proportion of hyperglycemic values. Pharmacists provided standardization, validation, education, and assisted with implementation to streamline transitions of care, monitoring methods, and drug‐laboratory interaction concerns.
- 12 February 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 36 (3) , 606-613
Clinical Utilization of Stress Dose Hydrocortisone in Adult Patients With Septic Shock: A Retrospective Observational Study at a Large Academic Medical Center
Background: The use of stress dose corticosteroids, specifically, hydrocortisone, in septic shock is heterogeneous, and current clinical trials yield conflicting results. Regardless, they are still recommended by guidelines for vasopressor-dependent septic shock. Objectives: This study sought to characterize current practice of hydrocortisone use in patients with septic shock and secondarily to compare clinical outcomes of those who received hydrocortisone to those who did not. Methods: This single center, retrospective cohort study evaluated patients with septic shock admitted to a tertiary care center between 2012 and 2017. Patients receiving hydrocortisone for at least two doses were compared to those without. Results: 3411 septic shock patients were included; 1593 (47%) received hydrocortisone and 1818 (53%) did not. Patients who received hydrocortisone had higher lactate (4.0 vs 3.4 mmol/L; P < .01) and Acute Physiology and Chronic Health Evaluation (APACHE) III scores (104.1 vs 91.0; P < .01). Vasopressor duration was 1.7 days longer in the hydrocortisone group ( P < .01), and the hydrocortisone group had higher hospital mortality (52% vs 38%; P < .01). A propensity score–matched population was conducted in patients with APACHE scores >100: vasopressor duration was longer in those who received hydrocortisone (3.9 vs 2.0 days; P < .01), and hospital mortality was higher (59.3% vs 53.1%; P = .036); however, after multivariable adjustment, no association between receipt of hydrocortisone and hospital mortality was detected (OR 1.2 [95% CI .9–1.6]). Conclusions: Patients who received hydrocortisone were more severely ill than those that did not, making retrospective evaluation of this question challenging. These results highlight the wide variability and heterogeneity in hydrocortisone use in clinical practice.
- 12 February 2022
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 36 (3) , 606-613
Clinical Utilization of Stress Dose Hydrocortisone in Adult Patients With Septic Shock: A Retrospective Observational Study at a Large Academic Medical Center
Background: The use of stress dose corticosteroids, specifically, hydrocortisone, in septic shock is heterogeneous, and current clinical trials yield conflicting results. Regardless, they are still recommended by guidelines for vasopressor-dependent septic shock. Objectives: This study sought to characterize current practice of hydrocortisone use in patients with septic shock and secondarily to compare clinical outcomes of those who received hydrocortisone to those who did not. Methods: This single center, retrospective cohort study evaluated patients with septic shock admitted to a tertiary care center between 2012 and 2017. Patients receiving hydrocortisone for at least two doses were compared to those without. Results: 3411 septic shock patients were included; 1593 (47%) received hydrocortisone and 1818 (53%) did not. Patients who received hydrocortisone had higher lactate (4.0 vs 3.4 mmol/L; P < .01) and Acute Physiology and Chronic Health Evaluation (APACHE) III scores (104.1 vs 91.0; P < .01). Vasopressor duration was 1.7 days longer in the hydrocortisone group ( P < .01), and the hydrocortisone group had higher hospital mortality (52% vs 38%; P < .01). A propensity score–matched population was conducted in patients with APACHE scores >100: vasopressor duration was longer in those who received hydrocortisone (3.9 vs 2.0 days; P < .01), and hospital mortality was higher (59.3% vs 53.1%; P = .036); however, after multivariable adjustment, no association between receipt of hydrocortisone and hospital mortality was detected (OR 1.2 [95% CI .9–1.6]). Conclusions: Patients who received hydrocortisone were more severely ill than those that did not, making retrospective evaluation of this question challenging. These results highlight the wide variability and heterogeneity in hydrocortisone use in clinical practice.